At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 13,299 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
In Brief
A Phase 3 clinical trial evaluating Tirzepatide and Dulaglutide for Type 2 Diabetes Mellitus. Completed, enrolled 13,299 participants across 635 sites in 31 countries.
Detailed Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMay 2020
Primary CompletionJun 2025
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartMay 29, 2020
Primary CompletionJun 12, 2025
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 6.4 years ago
Interventions
Tirzepatidedrug
Administered SC
Dulaglutidedrug
Administered SC